CCS/ACC JOINT PLENARY: MULTIDISCIPLINARY HEART FAILURE TEAM: MEETING FUTURE DEMANDS /PLÉNIÈRE COMMUNE CCS/ACC : ÉQUIPE MULTIDISCIPLINAIRE D'INSUFFISANCE CARDIAQUE : RÉPONDRE AUX BESOINS FUTURS

Saturday, October 28, 2023

14:00 – 15:00 EST

Location: Palais, 517D

Target Audience: Academic center clinicians, Community Cardiologists, Trainees, Nurses, Allied health professionals

Co-Chair(s)

Cathie Biga (she/her/hers)

Vice President
American College of Cardiology
Sean Virani, MD, MSc, MPH, FRCPC, FCCS (he/him/his)

Vice-President | Medical and Academic Affairs | Provincial Health Services Authority
UBC
St. Paul's Hospital | Providence Health Care

Planning Committee Chair(s)

Shelley Zieroth, MD

Heart Failure Cardiologist, Past President CHFS
St. Boniface Hospital
University of Manitoba

Planning Committee Member(s)

Grace Chua

Staff Cardiologist
Mackenzie Health
CM

Caroline McGuinty, MD FRCPC

Cardiologist
CCS, CCTN
University of Ottawa
IR

Idan Roifman, MD, MSc

Cardiologist and Director of Multi-Modality Imaging and Non-Invasive Cardiology
Sunnybrook Health Sciences Centre, University of Toronto; President, Canadian Society of Cardiovascular MRI
University of Toronto
SS

Shekoofeh Saboktakin Rizi
KS

Kyla Siatecki

Nurse Practitioner
Ricky Turgeon, BSc(Pharm), ACPR, PharmD

Assistant Professor / Pharmacist
University Of British Columbia
University of British Columbia

Disclosure(s):

Shelley Zieroth, MD: Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); BMS: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Cytokinetics: Consultant/Advisory Board (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Consultant/Advisory Board (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Otsuka: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Roche: Speaker/Honoraria (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Vifor: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Grace L. Chua: Amgen: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingleheim--Eli Lilly Alliance: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bristol Myers Squibb: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Gilead: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Moderna: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Regeneron: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Sanofi: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Takeda: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Vertex Pharmaceuticals: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Caroline M. McGuinty, MD FRCPC: Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Speaker/Honoraria (Ongoing); Pallium Canada: Speaker/Honoraria (Ongoing)

Idan Roifman, MD, MSc: No financial relationships to disclose

Ricky D. Turgeon, BSc(Pharm), ACPR, PharmD: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

discuss the trajectory of the future HF clinical care burden (Professional);
recognize short-term and long-term system solutions to the HF provider crisis (Health Advocate);
identify the recognized subspecialties and allied health disciplines within HF practice (Collaborator); and
propose training solutions and team to the HF provider crisis (Leader).

4 talks will highlight the looming HF provider crisis from the perspective of interdisciplinary team members. Each talk will include 1 polling question for interactivity. The session will conclude with a roundtable panel discussion of existing and potential North American solutions to meet the upcoming HF care requirements.